PrecisionMed is a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics
Biospecimen provider BioIVT has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics.
Based in Carlsbad, CA, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and it has the largest private, global repository of longitudinally collected human CSF for scientific research. Its collection contains both normal and diseased CSF samples together with other matched biofluids, such as plasma, sera, and whole blood.
"We are thrilled to announce BioIVT’s acquisition of PrecisionMed. Our vision is to lead the biospecimen industry through expertise and innovation and our acquisition of PrecisionMed pushes us even closer to this goal. We are excited about the possibilities that lie ahead as we expand our supply network and inventory and strengthen our capacity to meet the increasing customer demand for CSF and liquid biopsy products. Together, we will drive even greater value for our customers and further our mission of enabling smarter science,” said BioIVT CEO Richard Haigh, PhD.
“The vision at PrecisionMed has always been centered around positively impacting patients’ lives through fueling innovation and scientific discovery. We have long viewed BioIVT as the gold standard in our industry with the track record and global reach to back that up. This partnership magnifies our collective ability to reach the research community and impact patient lives. We are proud to pair our talent and resources with the world-class team at BioIVT,” said PrecisionMed CEO Eric Leach.
The vision at PrecisionMed has always been centred around positively impacting patients’ lives through fueling innovation and scientific discovery
- PrecisionMed CEO Eric Leach
PrecisionMed’s regulatory-compliant and privacy-protected biorepository contains more than 170,000 samples of CSF, whole blood, serum, plasma, PBMCs, and urine collected under Institutional Review Board-approved clinical protocols. This extensive collection of high-quality, well annotated biospecimens was amassed from PrecisionMed’s sizable network of donors and collection sites. Each biospecimen includes detailed clinical data, such as the donor’s diagnosis, demographics, family medical histories, treatment responses, and disease progression.
Underscoring the value of its contributions, PrecisionMed has received more than 120 citations in scientific journals and its collections have been part of U.S. NIH grants and have formed the basis of US FDA submissions and subsequent US FDA clearance for diagnostics.
Looking ahead, PrecisionMed will continue to operate out of its current headquarters and maintain its existing network of donor and collection sites. Financial details about this transaction were not disclosed.